# The Chemours Company (CC) · Edgar & Edgarette company card

> The Chemours Company (CC) grew revenue 0.4% in FY2025 to $5.8 billion, equity 3.4% of assets, and its dividend per share fell in the latest year on record. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1627223 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/CC) · [JSON](https://www.pops4.com/boards/company/CC.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $5.8B |
| Revenue growth, 1 year | 0.4% |
| Revenue growth per year | -2.2% |
| Operating margin | — |
| Net margin | -6.6% |
| Operating cash flow | $264M |
| Capital spending | $213M |
| Free cash flow | $51M |
| Cash | $670M |
| Long-term debt | $4.2B |
| Total assets | $7.4B |
| Total equity | $250M |
| Equity ÷ assets | 3.4% |
| Return on equity | -154.4% |
| Dividend per share | $0.5125 |
| Dividend years rising | 0 |

## Readings, computed from those figures

- Piotroski F: 5 of 9 (middling)
- Beneish M: -2.9 (below the −1.78 line)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: Steady earner · steady and paying a dividend, with average cash

## Edgarette's reading

Exposure: revenue $5.8B (FY2025), total debt $4.2B. Experience: revenue up 0.4% on the year, down 2.2% a year over 4 years. Soundness: equity 3.4% of assets, return on equity -154.4%, the dividend per share fell in the latest year on record. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $4.9B and $6.2B next year (method v4.1: its own 4-year record of growth weighed at 50% against $1B–10B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $4.5B to $6.8B. A statistical range, not company guidance. Against peers (9 filers, $50M+ revenue, chemicals & allied products): growth 0.4% against 0.4%.

Range logged 2026-09-25, receipt 587e4e90c93f8f4e, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-04-30 ([filing](https://www.sec.gov/Archives/edgar/data/1627223/000119312526193216/0001193125-26-193216-index.htm))

## Recent filings

- 8-K · filed 2026-11-02 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1627223/000162722326000032/0001627223-26-000032-index.htm)
- 8-K · filed 2026-09-10 · 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1627223/000162722326000029/0001627223-26-000029-index.htm)
- 8-K · filed 2026-09-09 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1627223/000162722326000027/0001627223-26-000027-index.htm)
- 10-Q · filed 2026-08-05 · [filing](https://www.sec.gov/Archives/edgar/data/1627223/000162722326000024/0001627223-26-000024-index.htm)
- 8-K · filed 2026-08-04 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1627223/000162722326000021/0001627223-26-000021-index.htm)
- 8-K · filed 2026-06-24 · 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1627223/000162722326000017/0001627223-26-000017-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001627223.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1627223

## Cite

POPS4, Edgar & Edgarette: The Chemours Company (CC) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/CC. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.